Histone modifications and depression: epigenetic mechanisms, therapeutic targets, and translational outlook
Frontiers in Genetics · 12.01.2026 · 16
DOI: 10.3389/fgene.2025.1722453 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Genetics, online erschienen am 12.01.2026. Verfasst von Liang-Zhen Lv und 11 weiteren Autor:innen. Beteiligte Einrichtung: Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Heilongjiang Province.
Themen: Depression
Abstract (Originalsprache)
Major depressive disorder (MDD) is a highly prevalent and heterogeneous psychiatric disorder shaped by the interplay of genetic, environmental, and epigenetic factors. Histone modifications, particularly acetylation and methylation, have emerged as critical regulators of chromatin dynamics and gene expression in stress adaptation, neuroplasticity, and emotional regulation. This review synthesizes current evidence linking dysregulated histone deacetylases (HDACs) and histone methyltransferases (HMTs) to impaired neuroplasticity, neuroinflammation, mitochondrial dysfunction, and hypothalamic–pituitary–adrenal (HPA) axis hyperactivity in depression. We further evaluate the therapeutic potential of HDAC and HMT inhibitors, highlight their effects beyond transcriptional control, and discuss peripheral epigenetic biomarkers as candidate tools for patient stratification and treatment prediction. Emerging technologies, including single-cell and spatial epigenomics as well as CRISPR-based epigenetic editing, are outlined as future avenues toward precision medicine. While isoform specificity, off-target effects, and translational heterogeneity remain major challenges, targeting histone modifications represents a promising strategy for next-generation antidepressant development.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.
- Zhejiang Chinese Medical University, Hangzhou, China.
- Yichun Central Hospital, Yichun, Heilongjiang, China.
- First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.
- Shunde Women and Children's Hospital, Guangdong Medical University, Foshan, Guangdong, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Heilongjiang Province
Zitieren
APA
Lv, L. Z., Wang, Z. D., Ren, J. J., Li, L. H., Liu, X. B., Li, J. L., Zhu, H., Jiang, B., Han, Y. P., Zhou, X. M., Ren, L., & Chang, Z. (2026). Histone modifications and depression: epigenetic mechanisms, therapeutic targets, and translational outlook. Frontiers in Genetics, 16. https://doi.org/10.3389/fgene.2025.1722453
Vancouver
Lv LZ, Wang ZD, Ren JJ, Li LH, Liu XB, Li JL, et al. Histone modifications and depression: epigenetic mechanisms, therapeutic targets, and translational outlook. Frontiers in Genetics. 2026;16. doi:10.3389/fgene.2025.1722453
BibTeX
@article{Lv2026,
author = {Lv, Liang-Zhen and Wang, Zhao-Di and Ren, Jia-Jie and Li, Lu-Hao and Liu, Xian-Bao and Li, Jia-Li and Zhu, Hui and Jiang, Bei and Han, Ya-Peng and Zhou, Xue-Ming and Ren, Li and Chang, Zhuo},
title = {Histone modifications and depression: epigenetic mechanisms, therapeutic targets, and translational outlook},
journal = {Frontiers in Genetics},
year = {2026},
volume = {16},
doi = {10.3389/fgene.2025.1722453}
}
EUVIMED